Nicholas Palermo

Title: Innovations by Nicholas Palermo in Cancer Treatment

Introduction

Nicholas Palermo is an accomplished inventor based in Omaha, NE, with a focus on developing innovative solutions for cancer treatment. He holds a total of four patents, showcasing his commitment to advancing medical science and improving patient outcomes.

Latest Patents

Palermo's latest patents include groundbreaking work on 14-3-3 targeting peptides for cancer treatment. These systems and methods are designed for the treatment of squamous cell carcinoma and other cancers. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. His peptide compositions include various structures, such as a first targeting peptide comprising Trp-Tyr-Trp-Lys-NH (SEQ ID NO: 1) and a second targeting peptide with a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH (SEQ ID NO: 2). Additionally, a third targeting peptide includes a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH (SEQ ID NO: 3).

Career Highlights

Throughout his career, Nicholas has worked with notable organizations, including Nutech Ventures and Creighton University. His contributions to these institutions have been instrumental in advancing research and development in the field of cancer treatment.

Collaborations

Some of his coworkers include Laura Hansen and Sandor Lovas, who have collaborated with him on various projects aimed at enhancing cancer therapies.

Conclusion

Nicholas Palermo's innovative work in developing targeting peptides for cancer treatment exemplifies his dedication to improving healthcare solutions. His patents and collaborations reflect a significant contribution to the medical field, particularly in the fight against cancer.